Airsculpt Technologies Inc Revenue per Employee (AIRS), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Airsculpt Technologies Inc   (NASDAQ: AIRS)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

Airsculpt Technologies Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Airsculpt Technologies Inc 's Revenue per employee fell on a trailing twelve month basis to $ 406,818, below the company average number of $434,069.
Within the Healthcare sector Employees of 222 other companies have achieved higher revenue per employee. While Airsculpt Technologies Inc 's total ranking has deteriorated compared to the previous quarter from 1531 to 1858. Airsculpt Technologies Inc has 363 employees.


What is Sales per Employee Ratio?







AIRS Revenue per Employee (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Revenue Change -8.71 % -2.53 % 0.05 % -14.64 % -17.76 %
Sales per Employee (TTM) $ 406,818 415,218 418,281 418,231 434,033
AIRS's Total Ranking # 1858 # 1531 # 1733 # 211 #
Seq. Revenue Change -25.54 % 8.91 % 17.78 % -4.43 % -20.49 %


Revenue per Employee Company Ranking
Within: No.
Healthcare Facilities Industry # 11
Healthcare Sector # 223
Overall Market # 1858

Revenue per Employee Statistics
High Average Low
$ 544,694 $ 434,069 $ 95,457
(Mar 31 2024)   (Sep 30 2021)



Financial Statements
Airsculpt Technologies Inc 's Revenue MRQ $ 32 Millions Visit AIRS's Income Statement
Airsculpt Technologies Inc 's Revenues TTM $ 148 Millions Visit AIRS's aggregate revenue growth
What are AIRS's Sales? Visit AIRS's Sales by Segment


  News about Airsculpt Technologies Inc Revenue per employee

AirSculpt Technologies Faces Uncertain Future Amid Leadership Changes and Declining Employee Productivity,

By Miami Beach, Fla. — AirSculpt Technologies, Inc. (NASDAQ: AIRS) is implementing strategic changes and updating projections for fiscal year 2024, yet the company s recent performance metrics signal a tougher road ahead. With the company gearing up to present at the ICR Conference 2025, questions linger about its capacity to regain traction in an increasingly competitive landscape.On January 13, 2025, AirSculpt issued a press release updating guidance for fiscal 2024. This announcement coincided with Yogi Jashnani’s recent appointment as CEO, effective January 7, 2025, succeeding Dennis Dean, who will transition back to his role as Chief Financial Officer. This significant leadership shift is positioned as a revitalization strategy, aimed at elevating the company s operational efficacy and market competitiveness.

AirSculpt Technologies Elevates Leadership with Yogi Jashnani as New CEO, Poised for Strategic Growth

In a significant move that underscores its commitment to innovation and excellence in the field of body contouring, AirSculpt Technologies, Inc. (NASDAQ:AIRS) has announced the appointment of Yogi Jashnani as the new Chief Executive Officer (CEO) and a member of the Board of Directors. This strategic leadership transition is set to take effect on January 7, 2025, with Yogi succeeding Dennis Dean, who has served as Interim CEO and will continue in his role as Chief Financial Officer.Miami Beach-based AirSculpt is recognized as a pioneering entity in the body contouring industry, specializing in premium procedures that cater to an increasingly discerning clientele. Under the leadership of Jashnani, the company is expected to harness his industry expertise and visionary outlook to drive further growth and enhance its competitive edge.




Other Ratios
Airsculpt Technologies Inc 's Income per Employee
Employees in Healthcare Facilities
Healthcare Facilities Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
AIRS's Revenue per Employee versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for AIRS's Competitors
Revenue per Employee for AIRS's Suppliers
Revenue per Employee for AIRS's Customers

You may also want to know
AIRS's Sales Growth Rates AIRS's Pe Price to earnings ratio AIRS's Receivables Turnover Ratio AIRS's Stock Quote
AIRS's Net Income Growth Rates AIRS's Ps Price to Sales ratio AIRS's Sales per Employee AIRS's Asset Turnover Ratio
AIRS's Net Margin AIRS's Pb Price to Book ratio AIRS's Financial Strength Ratios AIRS's Dividend Payout Ratio
Date modified: 2026-11-08T13:45:47+00:00




Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Sep 30 2026Number of Employees Sep 30 2026
Intuitive Surgical Inc   711,803.07 $ 12,115.600  Million 17,021 
Johnson and Johnson  705,504.26 $ 99,335.000  Million 140,800 
Mannkind Corporation  698,260.14 $ 413.370  Million 592 
Rhythm Pharmaceuticals Inc   678,135.27 $ 280.748  Million 414 
Inspire Medical Systems inc   661,810.95 $ 882.194  Million 1,333 
Caredx Inc   650,190.85 $ 497.396  Million 765 
Organon and Co   611,100.00 $ 6,111.000  Million 10,000 
Bioventus Inc   609,707.29 $ 585.319  Million 960 
Si bone inc   590,928.19 $ 222.189  Million 376 
Butterfly Network Inc   562,340.91 $ 123.715  Million 220 
Beone Medicines Ltd   550,523.25 $ 6,606.279  Million 12,000 
Novavax inc   549,598.13 $ 411.649  Million 749 
Henry Schein Inc   549,360.00 $ 13,734.000  Million 25,000 
Bausch Health Companies Inc   547,438.42 $ 11,113.000  Million 20,300 
Iradimed Corporation  538,192.16 $ 89.340  Million 166 
Glaukos Corp  528,660.88 $ 578.355  Million 1,094 
Angiodynamics Inc   512,316.46 $ 323.784  Million 632 
Resmed Inc   505,115.57 $ 5,743.164  Million 11,370 
Avantor Inc   491,525.93 $ 6,635.600  Million 13,500 
Lexicon Pharmaceuticals Inc   475,765.43 $ 38.537  Million 81 
Stryker Corp  469,642.86 $ 26,300.000  Million 56,000 
Monte Rosa Therapeutics Inc   468,833.33 $ 70.325  Million 150 
Dexcom Inc   459,900.90 $ 5,104.900  Million 11,100 
Medpace Holdings Inc   457,804.03 $ 2,838.385  Million 6,200 
Haemonetics Corporation  457,405.56 $ 1,382.737  Million 3,023 
Novocure Limited  451,955.14 $ 725.388  Million 1,605 
Omniab Inc   451,808.99 $ 40.211  Million 89 
Teladoc Health Inc   440,739.82 $ 2,468.143  Million 5,600 
Adc Therapeutics Sa  439,756.48 $ 84.873  Million 193 
Orthopediatrics Corp  437,981.73 $ 263.665  Million 602 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.